Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Immunotherapeutics firm Neovacs SA grosses €10mm in IPO

Executive Summary

Neovacs SA (active immunotherapies inhibiting cytokines) raised €10mm ($13.6mm) in its IPO on NYSE Euronext's Alternext exchange. The company had originally planned to sell up to 3.8mm shares for €5.20-6.00, but then lowered both the number of shares and price range to 2.3mm shares between €4.80-5.60. It ended up offering 2.1mm shares--most of which were bought by institutional investors, and the rest by individuals--at €4.80.
Deal Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies